hVIVO (LON:HVO) Trading 11.6% Higher - Time to Buy?

Key Points

• hVIVO plc shares rose by 11.6% on Monday, reaching a high of GBX 8 ($0.11), with trading volume significantly above average at 7.27 million shares.
• Wall Street analysts have a positive outlook for hVIVO, with two analysts giving a Buy rating and an average price target of GBX 23.
• The company reported a quarterly EPS of GBX (0.29) with a net margin of 25.96% and a return on equity of 47.93%.

hVIVO plc (LON:HVO - Get Free Report) shares were up 11.6% on Monday . The company traded as high as GBX 8 ($0.11) and last traded at GBX 7.70 ($0.10). Approximately 7,274,497 shares traded hands during mid-day trading, an increase of 146% from the average daily volume of 2,958,236 shares. The stock had previously closed at GBX 6.90 ($0.09).

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HVO. Shore Capital dropped their price target on hVIVO from GBX 35 to GBX 25 and set a "buy" rating for the company in a research report on Tuesday, September 23rd. Peel Hunt reaffirmed an "add" rating and set a GBX 21 price target on shares of hVIVO in a research note on Tuesday, July 29th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of GBX 23.

hVIVO Stock Performance

The company has a market cap of £52.92 million, a PE ratio of 1,000.00 and a beta of 0.97. The stock's 50 day simple moving average is GBX 9.27 and its two-hundred day simple moving average is GBX 12. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.

hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, research analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.